Navigation Links
MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
Date:9/2/2009

WILMINGTON, Delaware, September 2 /PRNewswire/ -- According to a new market research report, 'Global biosimilars Market (2009 - 2014)', published by MarketsandMarkets (http://www.marketsandmarkets.com), the global biosimilars market is expected to be worth US$19.4 billion by 2014, recording a CAGR of 89.1% from 2009 to 2014. The increasing demand from patients, insurers, and government agencies to reduce the costs of blockbuster biopharmaceuticals has created numerous opportunities in the global biosimilars market.

Browse more than 60 market data tables and in-depth TOC on biosimilars market. Early buyers will receive 10% customization of reports.

http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

Currently, the biosimilars market is highly fragmented and its huge opportunities are attracting new players. Favourable regulatory developments in the biosimilars sector are expected to increase the market share and profit margins while reducing medical expenditure.

Asia's early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars product market. The American market (including North America and Latin America) is expected to account for nearly 35.3% of the total revenues in 2014. The European market is also gaining momentum after the approval of its first biosimilars Omnitrope in 2006.

Recombinant non-glycosylated proteins form the largest segment in biosimilars market, with an estimated $11.5 billion by 2014. This market has a high CAGR of 87.9% from 2009 to 2014 mainly because most of the branded blockbuster biopharmaceutical drugs such as interferon, human growth hormone (Somatropin), insulin and G-CSF, belong to this class and have wide range of applications.

    Scope of the Report

    This report aims to identify and analyze biosimilars market on
    the basis of products, services, technology, and applications.

    - Biosimilars product market

    Peptides, recombinant glycosylated proteins, recombinant
    non-glycosylated proteins, and others

    - Biosimilars service market

    Contract research and manufacturing services, clinical trials
    services

    - Biosimilars applications market

    Oncology, infectious diseases, chronic and autoimmune
    diseases, and other diseases

    - Biosimilars technology market

    Recombinant DNA technology, monoclonal antibodies technologies,
    protein sequencing, bioassay, chromatography, nuclear magnetic
    resonance, and mass spectrometry

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.

Analyst Briefings on 22nd Sep 2009 The Biotech practice at MarketsandMarkets is pleased to announce its Analyst Briefing Presentation on the Global Biosimilar market to be held on 22 Sep 2009. The briefing on the Global Biosimilar Market (2009-2014) will benefit the Active pharmaceutical ingredients (APIs) manufacturers, contract research organizations, biosimilar drug manufacturers, medical/pharma associations, research labs, healthcare service providers, regulatory authorities, and technology providers.

To register your participation, please click here http://www.marketsandmarkets.com/AnalystBriefing/analyst-briefing-global- biosimilar-market.asp

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

About MarketsandMarkets

MarketsandMarkets is a research and consulting firm that publishes 120 market research reports per year. Each strategically analyzed report contains 250 pages of valuable market data, including more than 100 market data summary tables and in-depth, five-level segmentation for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports also analyze about 200 patents, over 50 companies and micro markets that are mutually exclusive and collectively exhaustive. Browse all our 120 titles at http://www.marketsandmarkets.com.

    Contact:

    Ms. Sunita
    108, West 13th Street,
    Wilmington, DE, 19801
    County of New Castle
    Tel: +1-888-989-8004
    Email: sales@marketsandmarkets.com


'/>"/>
SOURCE Markets and Markets
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
2. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
3. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
4. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
5. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
6. Global Biomaterials Market Worth US$58.1 Billion by 2014
7. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
8. Elsevier Global Medical News Launches H1N1 Channel
9. NexInfo Solutions, Inc. Selected by Beckman Coulter to Design and Streamline Global Sales & Operations Planning Processes
10. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
11. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):